- Home
- HWC vs PRAX Comparison
HWC vs PRAX Comparison
Compare HWC & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HWC
- PRAX
- Stock Information
- Founded
- HWC 1883
- PRAX 2015
- Country
- HWC United States
- PRAX United States
- Employees
- HWC N/A
- PRAX N/A
- Industry
- HWC Major Banks
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- HWC Finance
- PRAX Health Care
- Exchange
- HWC Nasdaq
- PRAX Nasdaq
- Market Cap
- HWC 4.7B
- PRAX 4.0B
- IPO Year
- HWC N/A
- PRAX 2020
- Fundamental
- Price
- HWC $57.11
- PRAX $198.76
- Analyst Decision
- HWC Strong Buy
- PRAX Strong Buy
- Analyst Count
- HWC 6
- PRAX 13
- Target Price
- HWC $69.67
- PRAX $202.85
- AVG Volume (30 Days)
- HWC 1.0M
- PRAX 1.5M
- Earning Date
- HWC 10-14-2025
- PRAX 11-07-2025
- Dividend Yield
- HWC 3.21%
- PRAX N/A
- EPS Growth
- HWC 24.84
- PRAX N/A
- EPS
- HWC 5.57
- PRAX N/A
- Revenue
- HWC $1,434,483,000.00
- PRAX $7,765,000.00
- Revenue This Year
- HWC $11.05
- PRAX N/A
- Revenue Next Year
- HWC $5.19
- PRAX $33.33
- P/E Ratio
- HWC $10.25
- PRAX N/A
- Revenue Growth
- HWC 8.16
- PRAX 338.45
- 52 Week Low
- HWC $43.90
- PRAX $26.70
- 52 Week High
- HWC $64.66
- PRAX $206.71
- Technical
- Relative Strength Index (RSI)
- HWC 43.41
- PRAX 78.36
- Support Level
- HWC $55.75
- PRAX $191.39
- Resistance Level
- HWC $57.82
- PRAX $206.36
- Average True Range (ATR)
- HWC 1.93
- PRAX 15.68
- MACD
- HWC 0.00
- PRAX 4.77
- Stochastic Oscillator
- HWC 34.19
- PRAX 95.12
About HWC Hancock Whitney Corporation
Hancock Whitney Corp operates bank offices and financial centers. The company offers a range of traditional and online banking services to commercial, small business, and retail customers, providing a variety of transaction and savings deposit products, treasury management services, secured and unsecured loan products (including revolving credit facilities), letters of credit, and similar financial guarantees. The Bank provides trust and investment management services to retirement plans, corporations, and individuals and provides its customers access to investment advisory and brokerage products.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.